As far as the current state of play, these past three weeks we have seen three crucial positive readouts of data from leading programs. The first came from pfizer, the second came from moderna, and the third one this morning just came from astrazeneca and the team at oxford. These are three leading vaccine front runners, all three in late stage studies appear to be effective, the first to 95 effective in preventing covid19. Thatnity is expected to do late november, early december. That will set up an fda decision, all eyes turning to the agency to see how quickly they can approve it and for what subgroups of the population. Vaccineing on in the phase, but there is a lot going on and muchneeded positive news when you think about the surge that we have seen in cases, hospitalizations, and deaths. The fda approval, how quickly could they approve it, and what could keep them from being approved, and how is the fda ensuring confidence in the public in the safety of these vaccines . Guest i
Phone lines split up as usual this morning. Democrats, 202 7488000 is the number to call in. Republicans, 202 7488001. Independents, 202 7488002. You can also send us a text. That number, 202 7488003. If you do, please include your name and where you are from. You can catch up with us on social media, twitter and facebook. A very good monday morning to you. You can start calling in now. Theheadlines on this topic, first use of the vaccine maybe december 13. 40 million doses said to be available by the end of the month. That from the front page of usa today. Frontline gets the first vaccine doses, but then who . Thats the question we are asking this morning, asking you to be in the position of setting the priority, how would you do it . Turning to the cdc webpage there, i q a on how the cdc is making its covid19 vaccine recommendations. Making those disease vaccine recommendations based on the input from the Advisory Committee on immunization practices. Its a federal Advisory Committee
Here on cspan. Is the Health Care Reporter focusing on the pharmaceutical biotech industry for Business Insider and joins us via zoom for a deep dive into the topic of Coronavirus Vaccine. It has been hard to keep up with the news of the past two weeks. Take us through what you expect in the coming days and weeks. What we should be watching for this week. Guest thanks for having me, john. That makes two of us as far as trying to keep on top of everything. As far as the current state of play, these past three weeks we have seen three crucial positive readouts of data from leading programs. The first came from pfizer, the second came from moderna, and the third one this morning just came from astrazeneca and the team at oxford. These are three leading vaccine front runners, all three in late stage studies appear to be effective, the first to 95 effective in preventing covid19. Thatnity is expected to do late november, early december. That will set up an fda decision, all eyes turning to
A market is going to shrink and shrink and so we look like greece looks up in the last 5 years the think of the normal slipping away groups that if lation and rent this lady should be ok stephen well im really glad that michael brought up the 2008 financial crisis as we have a reputation a reputation about it and it in this year where this was a artificially induced recession benefited the one percent you cant not keep stressing that year but what 202020 in 2008 have been common is that you have this massive transfer of wealth upward again upward again ok and so again i mean my underlying theme in this whole program is that half the country liberate speaking specifically about the United States that michaels reference to greece is a perfect one i think youre basically writing off tens of millions of people america hundreds of millions of people in the western more heads yeah i mean to do the work which sane. Is a process where the wealthy who go will they go through debts and this is s
It appears what is called the case shaped recovery is permanently dividing the country and to haves and have nots and this seems to be acceptable for those who are the house. To discuss this and more im joined by my guest Michael Hudson in new york is a professor of economics at the university of missouri kansas city and author of through give them their debts and in bangkok were joined by steve keen hes a crowdfunding professor of economics on a tree on as well as a distinguished Research Fellow of the institute for strategy resilience and security of University College london gentlemen crossed up rules in effect that means you can jump in anytime you want and i always appreciate it ok let me go to michael in new york you know this just term the new normal. Bandied about and what really worries me is the people that use the new normal where its a normal that is beneficial to them ok and theyre not particularly concerned about it ok because i hear more and more talk read more and more